Page last updated: 2024-08-26

yttrium radioisotopes and Pheochromocytoma, Extra-Adrenal

yttrium radioisotopes has been researched along with Pheochromocytoma, Extra-Adrenal in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Chua, WM; Huang, HL; Lam, WW; Loh, LM; Loke, KSH; Ng, DC; Ong, SYK; Tai, D; Tang, CYL; Tham, WY; Yan, SX1
Bongiovanni, A; Cittanti, C; Di Iorio, V; Di Mauro, F; Ferrara, M; Ibrahim, T; Lolli, I; Mezzenga, E; Nicolini, S; Paganelli, G; Sansovini, M; Scarpi, E; Severi, S; Tardelli, E; Zovato, S1
Caplin, M; Cheung, VTF; Khoo, B; Nastos, K; Navalkissoor, S; Quigley, AM; Toumpanakis, C1
Hanna, M; Mikko, T1
Forrer, F; Maecke, HR; Mueller-Brand, J; Riedweg, I1

Reviews

1 review(s) available for yttrium radioisotopes and Pheochromocytoma, Extra-Adrenal

ArticleYear
Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature.
    Journal of neuroendocrinology, 2023, Volume: 35, Issue:12

    Topics: Adrenal Gland Neoplasms; Humans; Paraganglioma; Pheochromocytoma; Receptors, Peptide; Retrospective Studies; Yttrium Radioisotopes

2023

Trials

2 trial(s) available for yttrium radioisotopes and Pheochromocytoma, Extra-Adrenal

ArticleYear
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.
    ESMO open, 2021, Volume: 6, Issue:4

    Topics: Adrenal Gland Neoplasms; Biomarkers; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Positron Emission Tomography Computed Tomography; Prognosis; Receptors, Somatostatin; Yttrium Radioisotopes

2021
Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2008, Volume: 52, Issue:4

    Topics: Adult; Female; Humans; Lutetium; Male; Middle Aged; Neoplasm Staging; Octreotide; Paraganglioma; Pheochromocytoma; Staining and Labeling; Yttrium Radioisotopes

2008

Other Studies

2 other study(ies) available for yttrium radioisotopes and Pheochromocytoma, Extra-Adrenal

ArticleYear
Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
    Journal of surgical oncology, 2017, Volume: 115, Issue:4

    Topics: 3-Iodobenzylguanidine; Acute Kidney Injury; Adrenal Gland Neoplasms; Adult; Aged; Chemotherapy, Adjuvant; Female; Humans; Male; Middle Aged; Octreotide; Organometallic Compounds; Paraganglioma; Pheochromocytoma; Radiopharmaceuticals; Retrospective Studies; Yttrium Radioisotopes

2017
[Radionuclide therapy for cancer--what's new?].
    Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:21

    Topics: Embolization, Therapeutic; Female; Finland; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Neoplasms; Neuroendocrine Tumors; Octreotide; Paraganglioma; Pheochromocytoma; Prostatic Neoplasms; Radiotherapy; Thyroid Neoplasms; Yttrium Radioisotopes

2012